Dr. Muzaffar Abbas

Home
Dr. Muzaffar Abbas

PROFESSOR / DEAN FACULTY OF PHARMACY

muzaffar.abbas@cust.edu.pk

+92-51-111-555-666

PROFILE SUMMARY

Dr. Muzaffar Abbas completed the PhD degree in Neuropharmacology under Fulbright Scholarship Program from South Dakota State University, USA, in 2016. He has more than 15 years of teaching and research experience in the country and abroad. Dr. Abbas worked at different positions including Lecturer, Assistant Professor, Associate Professor, Professor, Head of Department and Dean. He has broad research interests in the areas of neuroscience, molecular pharmacology and neuropharmacology. His specific field of research focuses on drug discovery and development for neurological disorders include depression, memory, anxiety, opioid tolerance, opioid-induced paradoxical pain, addiction, neuropathic and neuroinflammatory pain in laboratory animal models. Dr. Abbas has supervised post-graduate research projects. He won NRPU-2021 from Higher Education of Pakistan (HEC) on diabetic neuropathy. Dr. Abbas is member of Board of Studies of different organizations across the country. He remained member of Society for Neuroscience (SFN), USA, American Society for Pharmacology and Experimental Therapeutics (ASPET), USA and American Pain Society (APS), USA. He is life time member of The Rho Chi Honor Society, South Dakota State University, USA

QUALIFICATION
PhD	Pharmacology	Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University, USA	2016
MPhil	Pharmacology	Department of Pharmacy, University of Peshawar, Peshawar, KPK, Pakistan.	2009
B.Pharm	Pharmaceutical Sciences	Faculty of Pharmacy, Gomal University, Dera Ismail Khan, KPK, Pakistan	2005

TEACHING EXPERIENCE
Professor	Capital University of Science and Technology (CUST), Islamabad	Since – 2023
Associate Professor	Capital University of Science and Technology (CUST), Islamabad	2018 – 2023
Assistant Professor	Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad	2017 – 2018

MANAGEMENT EXPERIENCE
Dean	Faculty of Pharmacy, Capital University of Science & Technology, Islamabad	Since – 2020
HoD	Department of Pharmacy, Capital University of Science & Technology, Islamabad	2018 – 2020
HoD	Department of Basic Medical Sciences, Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad	2017 – 2018

MEMBERSHIP OF PROFESSIONAL BODIES
PASBAN	Member of Pakistan Society of Basic & Applied Neuroscience
AAPS	Member of American association of Pharmaceutical Sciences
PPA	Member of Pakistan Pharmacist Association (PPA)
SFN	Member of Society for Neuroscience (SFN), USA.
Rho Chi	Member of The Rho Chi Honor Society, South Dakota State University, USA
ASPET	Member of American Society for Pharmacology and Experimental Therapeutics (ASPET), USA.
APS	Member of American Pain Society (APS), USA
AAPM	Member of American Academy of Pain Management, USA

RESEARCH AREAS / INTERESTS
1.	Drug discovery
2.	Neurological Disorders
3.	Anxiety
4.	Opioid Tolerance

RESEARCH SUPERVISION
1.	PhD	Synthesis, Characterization, In silico and Pharmacological Investigation of New Benzimidazole Derivatives against Neurodegenerative diseases
2.	PhD	Pharmacological Studies and Herbal Drug Development of Saussurea lappa, Saussurea heteromalla and Related Species.
3.	MPhil	Synthesis, Characterization and Pharmacological Evaluation of 5-Substituted Isoxazole-3-Carboxamides
4.	MPhil	Studies on Neuropharmacological Effects of methoxy benzylidine cyclopentanone
5.	MPhil	Hepatoprotective Effect of Ginkgo Biloba Extract against Methotrexate Induced Hepatotoxicity in Rats
6.	MPhil	Synthesis, Pharmacological Investigation and Molecular Docking Studies of 4-Thiazolidinone Derivatives
7.	MPhil	Neuropharmacological Investigation of Telmisartan against Opioid Dependence and its Correlation in Mesolimbic System
8.	MPhil	Pharmacological Investigation of Benzimidazole Derivatives against Opioid-Induced Paradoxical Pain in Animal Models
9.	MPhil	Neuropharmacological effects of 2-[(Pyrrolidin-1-yl)Methyl]-1H-Benzimidazole against Opioid Tolerance during Anticancer-Induced Neuropathic Pain

SR.	JOURNAL PUBLICATIONS	YEAR
1	S. Alzarea, M. Abbas, P. J. Ronan, K. Lutfy, and S. Rahman, “The effect of an α-7 nicotinic allosteric modulator pnu120596 and NMDA receptor antagonist memantine on depressive-like behavior induced by LPS in mice: the involvement of brain microglia,” Brain Sciences, vol. 12, no. 11, p. 1493, 2022.	2022
2	H. Hussain, L. Rashan, U. Hassan, M. Abbas, F. L. Hakkim, and I. R. Green, “Frankincense diterpenes as a bio-source for drug discovery,” Expert Opinion on Drug Discovery, vol. 17, no. 5, pp. 513–529, 2022.	2022
3	S. Qureshi, G. Ali, M. Idrees, T. Muhammad, I.-K. Kong, M. Abbas, M. I. A. Shah, S. Ahmad, R. D. Sewell, and S. Ullah, “Selected thiadiazine-thione derivatives attenuate neuroinflammation in chronic constriction injury induced neuropathy,” Frontiers in Molecular Neuroscience, vol. 14, p. 728128, 2021.	2021
4	M. T. Khan, H. Nadeem, A. S. Sheikh, N. S. Malik, M. Rizwan, M. Imran, I. Javed, M. U. Munir, A.-u. Khan, A. Syed, M. Abbas, “Amino acid derivatives of 2-mercaptobenzimidazoles suppress cytokines at the site of inflammation and block gastric H+/K+ ATpase.” Pakistan Journal of Pharmaceutical Sciences, vol. 34, no. 3, pp. 1157-1163, 2021	2021
5	M. Abbas, S. Alzarea, R. L. Papke, and S. Rahman, “Effects of α7 nicotinic acetylcholine receptor positive allosteric modulator on BDNF, NKCC1 and KCC2 expression in the hippocampus following lipopolysaccharide-induced allodynia and hyperalgesia in a mouse model of inflammatory pain,” CNS & Neurological Disorders-Drug Targets, vol. 20, no. 4, pp. 366–377, 2021	2021
6	Z. Malik, M. Abbas, L. T. Al Kury, F. A. Shah, M. Alam, A.-u. Khan, H. Nadeem, S. Alghamdi, M. U. K. Sahibzada, and S. Li, “Thiazolidine derivatives attenuate carrageenan-induced inflammatory pain in mice,” Drug design, development and therapy, vol. 15, pp. 369–384, 2021.	2021
7	S. Akhtar, M. Abbas, K. Naeem, M. Faheem, H. Nadeem, and A. Mehmood, “Benzimidazole derivative ameliorates opioid-mediated tolerance during anticancer-induced neuropathic pain in mice,” Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), vol. 21, no. 3, pp. 365–371, 2021.	2021
8	M. T. Khan, H. Nadeem, A.-u. Khan, M. Abbas, M. Arif, N. S. Malik, Z. Malik, and I. Javed, “Amino acid conjugates of 2-mercaptobenzimidazole provide better anti-inflammatory pharmacology and improved toxicity profile,” Drug Development Research, vol. 81, no. 8, pp. 1057–1072, 2020.	2020
9	N. Ur Rehman, M. Al-Rashida, A. Tokhi, Z. Ahmed, F. Subhan, M. Abbas, M. A. Arshid, and K. Rauf, “Analgesic and antiallodynic effects of 4-fluoro-n-(4-sulfamoylbenzyl) benzene sulfonamide in a murine model of pain,” Drug Design, Development and Therapy, vol. 14, pp. 4511–4518, 2020.	2020
10	N. U. Rehman, K. Esmaeilpour, S. Joushi, M. Abbas, M. Al-Rashida, K. Rauf, and Y. Masoumi-Ardakani, “Effect of 4-fluoro-n-(4-sulfamoylbenzyl) benzene sulfonamide on cognitive deficits and hippocampal plasticity during nicotine withdrawal in rats,” Biomedicine & Pharmacotherapy, vol. 131, p. 110783, 2020.	2020
11	M. Sona Khan, W. Trenet, N. Xing, B. Sibley, M. Abbas, M. Al-Rashida, K. Rauf, and C. D. Mandyam, “A novel sulfonamide, 4-FS, reduces ethanol drinking and physical withdrawal associated with ethanol dependence,” International Journal of Molecular Sciences, vol. 21, no. 12, p. 4411, 2020.	2020
12	M. Imran, L. T. Al Kury, H. Nadeem, F. A. Shah, M. Abbas, S. Naz, A.-u. Khan, and S. Li, “Benzimidazole containing acetamide derivatives attenuate neuroinflammation and oxidative stress in ethanol-induced neurodegeneration,” Biomolecules, vol. 10, no. 1, p. 108, 2020.	2020
13	N. Rehman, M. Abbas, M. Rashida, A. Tokhi, M. A. Arshid, M. S. Khan, I. Ahmad, and K. Rauf, “Effect of 4-Fluoro-N-(4-Sulfamoylbenzyl) Benzene Sulfonamide on Acquisition and Expression of Nicotine-Induced Behavioral Sensitization and Striatal Adenosine Levels”. Drug Design, Development and Therapy, vol. 14, pp. 3777–3786, 2020.	2020
14	M. Abbas, S. Alzarea, R. L. Papke, and S. Rahman, “The α7 nicotinic acetylcholine receptor positive allosteric modulator prevents lipopolysaccharide-induced allodynia, hyperalgesia and TNF-α in the hippocampus in mice,” Pharmacological Reports, vol. 71, no. 6, pp. 1168–1176, 2019.	2019
15	F. A. Shah, G. Liu, L. T. Al Kury, A. Zeb, P.-O. Koh, M. Abbas, T. Li, X. Yang, F. Liu, Y. Jiang et al., “Melatonin protects MCAO-induced neuronal loss via NR2A mediated prosurvival pathways,” Frontiers in Pharmacology, vol. 10, p. 297, 2019.	2019
16	Z. Idris, M. Abbas, H. Nadeem, and A.-u. Khan, “The benzimidazole derivatives, B1 (N-[(1 H-benzimidazol-2-YL) methyl]-4-methoxyaniline) and B8 (N- 4-[(1 H-Benzimidazol-2-yl) Methoxy] Phenyl acetamide) attenuate morphine-induced paradoxical pain in mice,” Frontiers in Neuroscience, vol. 13, p. 101, 2019.	2019
17	H. Bibi, H. Nadeem, M. Abbas, and M. Arif, “Synthesis and anti-nociceptive potential of isoxazole carboxamide derivatives,” BMC chemistry, vol. 13, no. 6, pp. 1–13, 2019.	2019
18	T. Ahmed, A.-u. Khan, M. Abbass, E. R. Filho, Z. Ud Din, and A. Khan, “Synthesis, characterization, molecular docking, analgesic, antiplatelet and anticoagulant effects of dibenzylidene ketone derivatives,” Chemistry Central Journal, vol. 12, no. 134, pp. 1–18, 2018.	2018
19	M. Abbas, S. Alzarea, R. L. Papke, and S. Rahman, “The α7 nicotinic acetylcholine receptor positive allosteric modulator attenuates lipopolysaccharide-induced activation of hippocampal iκb and CD11B gene expression in mice,” Drug discoveries & therapeutics, vol. 11, no. 4, pp. 206–211, 2017	2017
20	N. Islam, M. Abbas, and S. Rahman, “Neuropathic pain and lung delivery of nanoparticulate drugs: An emerging novel therapeutic strategy,” CNS & Neurological Disorders-Drug Targets, vol. 16, no. 3, pp. 303–310, 2017.	2017
21	M. Abbas and S. Rahman, “Effects of alpha-7 nicotinic acetylcholine receptor positive allosteric modulator on lipopolysaccharide-induced neuroinflammatory pain in mice,” European Journal of Pharmacology, vol. 783, pp. 85–91, 2016.	2016
22	G. Ali, F. Subhan, M. Abbas, J. Zeb, M. Shahid, and R. D. Sewell, “A streptozotocin-induced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: validation using topical and systemic gabapentin,” Naunyn-schmiedeberg’s Archives of Pharmacology, vol. 388, pp. 1129–1140, 2015.	2015
23	M. Khan, F. Subhan, A.-u. Khan, M. Abbas, G. Ali, K. Rauf, and A. H. Gilani, “Nature cures nature: Hypericum perforatum attenuates physical withdrawal signs in opium dependent rats,” Pharmaceutical biology, vol. 52, no. 5, pp. 586–590, 2014.	2014
24	K. Rauf, F. Subhan, M. Abbas, S. M. Ali, G. Ali, M. Ashfaq, and G. Abbas, “Inhibitory effect of bacopasides on spontaneous morphine withdrawal induced depression in mice,” Phytotherapy Research, vol. 28, no. 6, pp. 937–939, 2014.	2014
25	G. Ali, F. Subhan, N. Islam, I. Khan, K. Rauf, S. Ullah, M. Abbas, and A. Rauf, “Input of isosteric and bioisosteric approach in drug design,” Journal of the Chemical Society of Pakistan, vol. 36, no. 1, pp. 150–169, 2014.	2014
26	H. Khan, M. Saeed, A. H. Gilani, M. H. Mehmood, N.-u. Rehman, N. Muhammad, M. Abbas, and I.-u. Haq, “Bronchodilator activity of aerial parts of polygonatum verticillatum augmented by anti-inflammatory activity: attenuation of ca2+ channels and lipoxygenase,” Phytotherapy Research, vol. 27, no. 9, pp. 1288–1292, 2013.	2013
27	M. Abbas, F. Subhan, K. Rauf, S. N.-u.-H. Mohani et al., “The involvement of non opioidergic mechanism in the antinociceptive and antilocomotive activity of bacopa monnieri,” Iranian Journal of Pharmacology and Therapeutics, vol. 11, no. 1, pp. 15–19, 2012.	2012
28	K. Rauf, F. Subhan, M. Abbas, I. u. Haq, G. Ali, and M. Ayaz, “Effect of acute and sub chronic use of bacopa monnieri on dopamine and serotonin turnover in mice whole brain,” African Journal of Pharmacy and Pharmacology, vol. 6, pp. 2767–2774, 2012.	2012
29	M. Ismail, S. Rahman, A. Zada, M. Abbas, T. Ali, and U. Niaz, “Analgesic, anti git motility and toxicological activities of pistacia integerrima stewart ex brandis bark in mice,” Journal of Medicinal Plants Research, vol. 6, no. 14, pp. 2827–2831, 2012.	2012
30	K. Rauf, F. Subhan, M. Abbas, A. Badshah, I. Ullah, and S. Ullah, “Effect of bacopasides on acquisition and expression of morphine tolerance,” Phytomedicine, vol. 18, no. 10, pp. 836–842, 2011.	2011
31	M. Abbas, F. Subhan, K. Rauf, M. Khan, and N. Mohani, “The involvement of biogenic amines in the antidepressant effect of bacopa monnieri,” Pharmacologyonline, vol. 1, pp. 112-123, 2011.	2011
32	M. Abbas, F. Subhan, N. Mohani, K. Rauf, G. Ali, and M. Khan, “The involvement of opioidergic mechanisms in the activity of bacopa monnieri extract and its toxicological studies,” African Journal of Pharmacy and Pharmacology, vol. 5, no. 8, pp. 1120–1124, 2011.	2011
33	S. Rahman, M. Ismail, M. Abbas, and N. Muhammad, “Study of antipyretic activity of Pistacia integerrima Stewart ex Brandis bark in Balb-C mice” Journal of Pharmacy Research, vol. 4, no. 12, pp. 4411-4412, 2011.	2011
34	F. Subhan, M. Abbas, K. Rauf, and A. Baseer, “Anti git motility, toxicological and phytochemical studies on bacopa monnieri,” Pharmacologyonline, vol. 3, pp. 937–950, 2010.	2010
35	F. Subhan, M. Abbas, K. Rauf, M. Arfan, R. Sewell, and G. Ali, “The role of opioidergic mechanism in the activity of bacopa monnieri extract against tonic and acute phasic pain modalities,” Pharmacologyonline, vol. 3, pp. 903–914, 2010.	2010

SR.	CONFERENCE PUBLICATIONS	YEAR
1	S. Rahman, and M. Abbas, “Effects of α7 nicotinic receptor positive allosteric modulator on sodium-potassium-chloride co-transporter 1 activation following lipopolysaccharide-induced neuroinflammatory pain in mice”, The FASEB Journal. Vol. 31, no. 1, pp. 812.2, 2017.	2017
2	M. Abbas, and S. Rahman, “Brain alpha-7 nicotinic receptor positive allosteric modulator attenuates mechanical allodynia and hyperalgesia in a mouse model of neuroinflammatory pain” The Journal of Pain. Vol. 17, no. 4, pp. S75, 2016.	2016
3	M. Abbas, and S. Rahman, “Antihyperalgesic and antiallodynic effects of 3a,4,5,9b-Tetrahydro-4-(1-naphthalenyl)-3H-cyclopentan[c] quinoline-8 sulfonamide in an animal model of neuroinflammatory pain” The FASEB Journal. Vol. 30, pp. 927.1., 2016.	2016
4	M. Abbas, and S. Rahman, “Effects of nicotinic acetylcholine receptor positive allosteric modulator on microglia activation following lipopolysaccharide-induced neuropathic pain” The FASEB Journal, vol. 29, pp. 770.14, 2015.	2015
5	Shafiqur Rahman, Muzaffar Abbas. Effects of nicotinic acetylcholine receptor positive allosteric modulator in a neuropathic pain model. The FASEB Journal. (2014), 28, 661.10.	2014

Our Team

Dr. Muzaffar Abbas

PROFILE SUMMARY

Other Members